French animal health company Virbac has introduced what it claims is a world-first innovation: medicated cat treats designed specifically for felines suffering from chronic kidney disease. The breakthrough product, unveiled on Thursday, consists of standard-looking cat croquettes coated with veterinary medication, offering a potential solution to one of the most challenging aspects of feline healthcare - treatment compliance.

The development addresses a significant problem in veterinary medicine. Chronic kidney disease affects approximately one-third of cats over eight years old, according to multiple studies cited by industry experts. While effective treatments exist, many cat owners struggle with administering medication to their pets, with research showing that 40-50% of owners eventually abandon treatment regimens due to their cats' refusal to swallow pills.

Manufactured at Virbac's facilities in Carros, located in the Alpes-Maritimes region, and Vauvert in the Gard department, the medicated croquettes combine a specific nutritional blend with a validated veterinary drug coating. The product will be available exclusively by prescription through veterinary clinics, ensuring proper medical supervision while simplifying the treatment process for both pets and their owners.

Virbac plans to launch the innovative product across nearly 30 European countries by the end of the year. Founded in 1968 by a Nice-based veterinarian, the publicly-traded company has grown into a global animal health leader with over 6,400 employees worldwide and reported €1.4 billion in revenue for 2024. This latest innovation represents the company's ongoing commitment to developing practical solutions for common veterinary challenges.